Trials / Recruiting
RecruitingNCT06493760
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 As First-Line Treatment in Metastatic Colorectal Cancer Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SSGJ-707 | bispecific antibody |
| DRUG | Bevacizumab | VEGF antibody |
| DRUG | Oxaliplatin | chemotherapy |
| DRUG | Capecitabine | chemotherapy |
| DRUG | Calcium Folinate | chemotherapy |
| DRUG | 5-fluorouracil | chemotherapy |
Timeline
- Start date
- 2024-09-03
- Primary completion
- 2025-06-01
- Completion
- 2027-06-01
- First posted
- 2024-07-10
- Last updated
- 2024-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06493760. Inclusion in this directory is not an endorsement.